Novo Nordisk (NVO.N) CEO: Liver disease is also a clear entry point; despite some recent setbacks, the cardiovascular field is another clear direction.

2026-09-21

Novo Nordisk (NVO.N) CEO: Liver disease is also a clear entry point; despite some recent setbacks, the cardiovascular field is another clear direction.